Systems biology and combination therapy in the quest for clinical efficacy
The DOI matches its Crossref record; 69 of the 69 references it cites were found in a registry or an index.
Abstract
Combinatorial control of biological processes, in which redundancy and multifunctionality are the norm, fundamentally limits the therapeutic index that can be achieved by even the most potent and highly selective drugs. Thus, it will almost certainly be necessary to use new 'targeted' pharmaceuticals in combinations. Multicomponent drugs are standard in cytotoxic chemotherapy, but their development has required arduous empirical testing. However, experimentally validated numerical models should greatly aid in the formulation of new combination therapies, particularly those tailored to the needs of specific patients. This perspective focuses on opportunities and challenges inherent in the application of mathematical modeling and systems approaches to pharmacology, specifically with respect to the idea of achieving combinatorial selectivity through use of multicomponent drugs.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Overall, these examples demonstrate the potential use of mechanistic and data driven modelling in dose selection, studies of drug-drug interaction, and identification of the most efficient therapies [338].”
From Cardiovascular disease models: A game changing paradigm in drug discovery and screening (2019) · cites this paper as [338]
In the citing paper
“Accurate predictions of combination treatments from single treatment data would allow a cost-effective pre-selection of promising drug candidates for experimental follow-up, which is highly relevant for modern personalized medicine (Fitzgerald et al., 2006).”
From Efficient Parameter Estimation Enables the Prediction of Drug Response Using a Mechanistic Pan-Cancer Pathway Model (2018) · cites this paper as Fitzgerald et al., 2006
Citations
Cites
Lipinski, C. A., Lombardo, F., Dominy, B. W., & Feeney, P. J. (2001) · Advanced Drug Delivery Reviews · doi:10.1016/s0169-409x(00)00129-0 · Cited by 18,139
Chou, T.-C., & Talalay, P. (1984) · Advances in Enzyme Regulation · doi:10.1016/0065-2571(84)90007-4 · Cited by 7,178
Arzneimittelforschung: Eine Zukunftsoption für Ärzte?
Bethke, T. D. (2012) · Der Pneumologe · doi:10.1007/s10405-012-0601-3 · Cited by 3,261
mTOR Inhibition Induces Upstream Receptor Tyrosine Kinase Signaling and Activates Akt
O'Reilly, K. E., Rojo, F., She, Q.-B., Solit, D., Mills, G. B., Smith, D., Lane, H., Hofmann, F., Hicklin, D. J., Ludwig, D. L., et al. (2006) · Cancer Research · doi:10.1158/0008-5472.can-05-2925 · Cited by 2,561 · cited 1×
“However, growth of cells in the presence of IGF-1 was found to be unaffected when mTOR was inhibited with a rapamycin analog; instead, activity of the upstream regulator Akt increase”
BackgroundRobustness in the Strategy of Scientific Model Building
Box, G. E. P. (1979) · Robustness in Statistics · doi:10.1016/b978-0-12-438150-6.50018-2 · Cited by 1,562
Enzyme and metabolic inhibitors
Webb, J. L. (1963) · Academic Press eBooks · doi:10.5962/bhl.title.7320 · Cited by 1,514
The search for synergy: a critical review from a response surface perspective.
Greco, W. R., Bravo, G., & Parsons, J. C. (1995) · Pharmacological Reviews · doi:10.1016/s0031-6997(25)06847-4 · Cited by 1,434
Berenbaum, M. C. (1989) · Pharmacological Reviews · doi:10.1016/s0031-6997(25)00026-2 · Cited by 1,414
Cell-signalling dynamics in time and space
Kholodenko, B. N. (2006) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm1838 · Cited by 1,347 · cited 1×
“However, large models with multiple signaling circuits raise new conceptual issues, such as how best to represent the partitioning of shared components (for example, Ras, MAP kinases and others) among potentially competing pathway”
BackgroundThe tor pathway: a target for cancer therapy
Bjornsti, M.-A., & Houghton, P. J. (2004) · Nature Reviews Cancer · doi:10.1038/nrc1362 · Cited by 1,314 · cited 1×
“Inhibition of mTOR is promising as an anticancer strategy, as many proteins lying upstream and downstream of mTOR are deregulated in a human cance”
Background
Cited by
Items 301–400 of 570
MEK and MCL-1 sequential inhibition synergize to enhance rhabdomyosarcoma treatment
Alcon, C., Martín, F., Prada, E., Mora, J., Soriano, A., Guillén, G., Gallego, S., Roma, J. M., Samitier, J., Villanueva, A., et al. (2022) · Cell Death Discovery · doi:10.1038/s41420-022-00959-w · Cited by 19
A Deep Neural Network for Predicting Synergistic Drug Combinations on Cancer
Yan, S., & Ding, Z. (2024) · Interdisciplinary Sciences Computational Life Sciences · doi:10.1007/s12539-023-00596-6 · Cited by 19
“The paradigm of “one drug, one target” has been pivotal in the realms of drug discovery and design [1, 2].”
Brown, J. B., Niijima, S., & Okuno, Y. (2013) · Molecular Informatics · doi:10.1002/minf.201300101 · Cited by 18
Roller, D. G., Capaldo, B. J., Bekiranov, S., Mackey, A. J., Conaway, M. R., Petricoin, E. F., Gioeli, D. G., & Weber, M. J. (2015) · Oncotarget · doi:10.18632/oncotarget.6548 · Cited by 19
“We scored synergy using the Bliss model of independence [76, 77] in part because it quantifies interactions even where one drug does not display cytotoxic effects as a single agent, a common occurrence with targeted therapies.”
Wu, Y., Zhang, D., Baofan, W., Quan, Y., Liu, D., Li, Y., & Zhang, X. (2017) · Chemical and Pharmaceutical Bulletin · doi:10.1248/cpb.c17-00261 · Cited by 18
Khan, I., Mahfooz, S., & Ansari, I. A. (2019) · Endocrine Metabolic & Immune Disorders - Drug Targets · doi:10.2174/1871530319666191125111920 · Cited by 18
Applications of personalised signalling network models in precision oncology
Hastings, J. F., O’Donnell, Y. E. I., Fey, D., & Croucher, D. R. (2020) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2020.107555 · Cited by 19
Combination treatment optimization using a pan-cancer pathway model
Schmucker, R., Farina, G., Faeder, J. R., Fröhlich, F., Saglam, A. S., & Sandholm, T. (2021) · PLoS Computational Biology · doi:10.1371/journal.pcbi.1009689 · Cited by 21
Micro- and Nanoscale Approaches in Antifungal Drug Discovery
Willaert, R. (2018) · Fermentation · doi:10.3390/fermentation4020043 · Cited by 18
“This genetic network organisation suggests that judicious combinations of small molecule inhibitors of both essential and non-essential targets may elicit additive or synergistic effects on cell growth [74,75].”
BackgroundPadmanabhan, P., & Dixit, N. M. (2015) · CPT Pharmacometrics & Systems Pharmacology · doi:10.1002/psp4.12005 · Cited by 18
“Synergy between drugs is thought to arise from an underlying interaction between the drugs or between the processes, pathways, and/or molecules they target.(34) For instance, we demonstrated recently that DAAs targeting viral replication can alter the systems-level properties of the interferon signaling network and im…”
BackgroundFuentealba-Manosalva, O., Mansilla, M., Buelvas, N., Martin-Martín, A., Torres, C. G., & López‐Muñoz, R. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24119705 · Cited by 18
“More precisely, the Bliss model assumes a multiplicative outcome when the effect is expressed as a fraction [6].”
MethodPatient derived tumoroids of high grade neuroendocrine neoplasms for more personalized therapies
April-Monn, S., Kirchner, P., Detjen, K. M., Bräutigam, K., Trippel, M., Grob, T. J., Statzer, C., Maire, R., Kollár, A., Chouchane, A., et al. (2024) · npj Precision Oncology · doi:10.1038/s41698-024-00549-2 · Cited by 20
Zhang, C., Zhai, S., Li, X., Zhang, Q., Wu, L., Liu, Y., Jiang, C., Zhou, H., Li, F., Zhang, S., et al. (2014) · Cell Death and Disease · doi:10.1038/cddis.2014.76 · Cited by 21
Ding, X., Chang, V. H. S., Li, Y., Li, X., Xu, H., Ho, C., Ho, D., & Yen, Y. (2019) · Advanced Therapeutics · doi:10.1002/adtp.201900127 · Cited by 18
Weiss, A., & Nowak-Sliwinska, P. M. (2017) · JALA Journal of the Association for Laboratory Automation · doi:10.1177/2211068216682338 · Cited by 17
Shaping Neonatal Immunization by Tuning the Delivery of Synergistic Adjuvants via Nanocarriers
Barman, S., Borriello, F., Brook, B., Pietrasanta, C., Leon, M. D., Sweitzer, C., Menon, M., van Haren, S. D., Soni, D., Saito, Y., et al. (2022) · ACS Chemical Biology · doi:10.1021/acschembio.2c00497 · Cited by 18
Antiangiogenic and cytotoxic activity of boswellic acid on breast cancer MCF-7 cells
Saraswati, S., & Agrawal, S. S. (2011) · Biomedicine & Preventive Nutrition · doi:10.1016/j.bionut.2011.09.006 · Cited by 17
Wildenhain, J., Spitzer, M., Dolma, S., Jarvik, N., White, R., Roy, M. M., Griffiths, E., Bellows, D. S., Wright, G. D., & Tyers, M. (2016) · Scientific Data · doi:10.1038/sdata.2016.95 · Cited by 18
An ecosystem framework for understanding and treating disease
Hochberg, M. (2018) · Evolution Medicine and Public Health · doi:10.1093/emph/eoy032 · Cited by 17
Qiao, M., Wu, D., Carey, M., Zhou, X., & Zhang, L. (2015) · PLoS ONE · doi:10.1371/journal.pone.0143206 · Cited by 16
“The Loewe additivity [28,29] evaluates whether the combination effect of BHQ880, GCs and Lidamycin is synergistic.”
BackgroundPrediction of whole-cell transcriptional response with machine learning
Eslami, M., Borujeni, A. E., Eramian, H., Weston, M., Zheng, G., Urrutia, J. A., Corbet, C., Becker, D., Maschhoff, P., Clowers, K. J., et al. (2021) · Bioinformatics · doi:10.1093/bioinformatics/btab676 · Cited by 19
Goltsov, A., Langdon, S. P., Goltsov, G., Harrison, D. J., & Bown, J. (2014) · Frontiers in Oncology · doi:10.3389/fonc.2014.00013 · Cited by 17
“(52) to investigate the modification of the I/O response of the down-stream pathways as a result of external and internal perturbations such as inhibition of signaling proteins and protein mutations.”
BackgroundBolan, P. O., Zviran, A., Brenan, L., Schiffman, J. S., Dusaj, N. N., Goodale, A. B., Piccioni, F., Johannessen, C. M., & Landau, D. A. (2019) · Cell Systems · doi:10.1016/j.cels.2019.10.002 · Cited by 15
Independent drug action and its statistical implications for development of combination therapies
Chen, C., Liu, F., Ren, Y., Suttner, L. H., Sun, Z., Shentu, Y., & Schmidt, E. V. (2020) · Contemporary Clinical Trials · doi:10.1016/j.cct.2020.106126 · Cited by 17
Lucia, M. B., Anu, R., Handley, M. D., Gillet, J.-P., Wu, C.-P., Donatis, G. M. D., Cauda, R., & GOTTESMAN, M. (2011) · British Journal of Cancer · doi:10.1038/bjc.2011.275 · Cited by 15
“Drug combinations were evaluated for their ability to promote resistance synergistically or additively using the Bliss Model of Independence (Fitzgerald et al , 2006).”
A Tick Antivirulence Protein Potentiates Antibiotics against Staphylococcus aureus
Abraham, N. M., Liu, L., Jutras, B. L., Murfin, K. E., Acar, A., Yarovinsky, T. O., Sutton, E., Heisig, M., Jacobs, C., & Fikrig, E. (2017) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00113-17 · Cited by 16
“Multidrug treatment is an alternative approach to control infection, especially for patients with extensive disease that is difficult to treat due to bacterial resistance or the location of the pathogen (16, 17).”
BackgroundSingle-trigger dual-responsive nanoparticles for controllable and sequential prodrug activation
Robertson, N., Yang, Y., Khan, I. A., LaMantia, V. E., Royzen, M., & Yigit, M. V. (2017) · Nanoscale · doi:10.1039/c7nr04138a · Cited by 15
Computational Drug Repurposing for Neurodegenerative Diseases
Savva, K., Zachariou, M., Oulas, A., Minadakis, G., Sokratous, K., Dietis, N., & Spyrou, G. M. (2019) · Elsevier eBooks · doi:10.1016/b978-0-12-816125-8.00004-3 · Cited by 15
Cokol, M. (2013) · Current Drug Discovery Technologies · doi:10.2174/1570163811310020003 · Cited by 15
“To find such new treatments, guided or random screens to find useful drug combinations have been conducted and methods to predict the intended effects and side effects of drug combinations have been proposed [42, 49-51].”
BackgroundZhang, H., Wang, X., Qu, P., Huangfu, Y., Liu, D., Wu, Y., Liu, Y., Chen, P., Mai, K., & Zhang, W. (2024) · Aquaculture Reports · doi:10.1016/j.aqrep.2024.102136 · Cited by 14
Zou, J., Luo, S., Wei, Y.-Q., & Yang, S. (2010) · Molecular BioSystems · doi:10.1039/c0mb00004c · Cited by 15
Biological Networks and Drug Discovery—Where Do We Stand?
Geppert, T., & Koeppen, H. (2014) · Drug Development Research · doi:10.1002/ddr.21207 · Cited by 16
“The observed phenotypic responses on the application of drug combinations could be very helpful in inferring network structure [Fitzgerald et al., 2006; Azmi et al., 2010].”
BackgroundExperimental designs for drug combination studies
Almohaimeed, B., & Donev, A. N. (2013) · Computational Statistics & Data Analysis · doi:10.1016/j.csda.2013.01.007 · Cited by 14
“[6, 7, 8, 9, 10, 11].”
Synergistic Interaction between Selective Drugs in Cell Populations Models
Doldàn-Martelli, V., & Míguez, D. G. (2015) · PLoS ONE · doi:10.1371/journal.pone.0117558 · Cited by 15
“On the other hand, drug combination therapies have shown enhanced efficiency compared to individual drug therapy in many diseases [16], including cancer [17, 18] and HIV’s [19].”
Engineering Simulations for Cancer Systems Biology
Bown, J., Andrews, P. S., Deeni, Y., Goltsov, A., Idowu, M. A., Polack, F., Sampson, A. T., Shovman, M. M., & Stepney, S. (2012) · Current Drug Targets · doi:10.2174/138945012803530071 · Cited by 16
Seguel, V., Castro, L., Reigada, C., Cortes, L. A., Díaz, M. V., Miranda, M. R., Pereira, C. A., Lapier, M., Campos‐Estrada, C., Morello, A., et al. (2016) · Experimental Parasitology · doi:10.1016/j.exppara.2016.10.007 · Cited by 16
“We choose the Bliss independence approach for the data analyzes, assuming that both drugs have different action mechanisms (Fitzgerald et al., 2006; Foucquier and Guedj, 2015).”
MethodZhang, Q., Zhai, S., Li, L., Li, X., Jiang, C., Zhang, C., & Yan, B. (2014) · Journal of Pharmacological Sciences · doi:10.1254/jphs.14050fp · Cited by 14
Sharma, A., & Rani, R. (2018) · Journal of Bioinformatics and Computational Biology · doi:10.1142/s0219720018500178 · Cited by 16
Zhai, Q., Chang, Z., Li, J., & Li, J. (2021) · Aquaculture · doi:10.1016/j.aquaculture.2021.737462 · Cited by 13
Microfluidic technologies for advanced antimicrobial susceptibility testing
Wu, W., & Mu, Y. (2024) · Biomicrofluidics · doi:10.1063/5.0190112 · Cited by 13
Woodall, M. N. J., Ellis, S., Zhang, S., Kembou-Ringert, J. E., Kite, K., Buggiotti, L., Jacobs, A. I., Agyeman, A. A., Masonou, T., Palor, M., et al. (2024) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01233-24 · Cited by 16
“High synergy scores > 10, such as those derived from Bliss independence models, have been linked to improved therapeutic outcomes as they reflect enhanced potency of drug combinations (44).”
Wang, T.-T., Hong, Y., Chen, Z., Wu, D., Yang, L., Wu, X., Huang, H., Zhang, Q., & Jia, C. (2021) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2021.04.047 · Cited by 13
Zhai, Q., Chang, Z., Li, J., & Li, J. (2022) · Antibiotics · doi:10.3390/antibiotics11121784 · Cited by 13
“Chinese herbal medicines and antibiotics work in different ways, such that their combinations can improve the treatment effect of various diseases and can decrease the emergence of antibiotic resistance [12].”
BackgroundBrako, F., Luo, C., Matharu, R. K., Ciric, L., Harker, A. H., Edirisinghe, M. J., & Craig, D. Q. M. (2020) · Pharmaceutics · doi:10.3390/pharmaceutics12040373 · Cited by 13
“In addition, localisation allows for the efficient targeting of tissues, thereby maximising drug efficacy while also minimising toxicity via the control of the selectivity of the region of the body exposed to the therapeutic agent [5].”
BackgroundLuo, K.-W., Ko, C., Yue, G. G., Gao, S., Lee, J. K.-M., Li, G., Fung, K., Leung, P., Evdokiou, A., & Lau, C. B. (2014) · Journal of Cancer Research and Clinical Oncology · doi:10.1007/s00432-014-1882-1 · Cited by 12
“Combination therapy, in which one or more medication or therapies are used at the same time, is the proven cure for cancer treatment (Fitzgerald et al. 2006).”
BackgroundNoise-precision tradeoff in predicting combinations of mutations and drugs
Tendler, A., Zimmer, A., Mayo, A., & Alon, U. S. (2019) · PLoS Computational Biology · doi:10.1371/journal.pcbi.1006956 · Cited by 12
“This question is important for developing effective combination therapy [5–9] and to reduce drug resistance [10–14].”
BackgroundMotamedian, E., Taheri, E., & Bagheri, F. (2017) · Cell Proliferation · doi:10.1111/cpr.12370 · Cited by 12
Behinaein, B., Rudie, K., & Sangrar, W. (2016) · IEEE Transactions on Computational Biology and Bioinformatics · doi:10.1109/tcbb.2016.2614301 · Cited by 12
“Synergy was assessed in the physiochemical model by comparing EGF-induced Erk output to outputs calculated using Bliss independence [6] and the principle of superposition.”
BackgroundMethodInfluentialKhatri, A., Brundage, R. C., Hull, J. M., Williams, B. W., Yee, D., & Kirstein, M. N. (2011) · The AAPS Journal · doi:10.1208/s12248-011-9308-3 · Cited by 11
Sbaraglini, M. L., Bellera, C. L., Braghini, J. Q., Areco, Y., Miranda, C., Carrillo, C., Kelly, J., Buchholz, B., Gelpi, R. J., Talevi, A., et al. (2019) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2019.111778 · Cited by 11
System and network biology-based computational approaches for drug repositioning
Pandita, V., Parihar, A., Parihar, D. S., Panda, S., Shanmugarajan, D., Kumari, L., & Badwaik, H. R. (2022) · Elsevier eBooks · doi:10.1016/b978-0-323-91172-6.00003-0 · Cited by 11
“In contrast to conventional treatment, which focuses on maximal tolerable doses, this can result in the finest medicine with great efficacy at the lowest toxicity levels conceivable for the unique individual (Sun et al., 2013; Fitzgerald et al., 2006).”
BackgroundLuo, D., Ratnayake, R., Atanasova, K. R., Paul, V. J., & Luesch, H. (2023) · Biochemical Pharmacology · doi:10.1016/j.bcp.2023.115608 · Cited by 11
Nazari, M., Taheri, M., Nouri, F., Bahmanzadeh, M., & Alikhani, M. Y. (2024) · Chemotherapy · doi:10.1159/000542826 · Cited by 11
Quantitative Evaluation and Optimization of Co-drugging to Improve Anti-HIV Latency Therapy
Wong, V. C., Fong, L. E., Adams, N. M., Xue, Q., Dey, S. S., & Miller‐Jensen, K. (2014) · Cellular and Molecular Bioengineering · doi:10.1007/s12195-014-0336-9 · Cited by 14
Amelioration of an undesired action of deguelin
Vrana, J. A., Boggs, N. T., Currie, H. N., & Boyd, J. W. (2013) · Toxicon · doi:10.1016/j.toxicon.2013.07.028 · Cited by 13
“One strategy involves the simultaneous inhibition of a single target using two or more compounds, while another strategy utilizes two inhibitors to attack two different proteins on a linear pathway (e.g. mitogenactivated protein kinase cascade) (Fitzgerald et al., 2006).”
InfluentialTesting the optimality properties of a dual antibiotic treatment in a two-locus, two-allele model
Peña‐Miller, R., Fuentes-Hernández, A., Reding, C., Gudelj, I., & Beardmore, R. (2014) · Journal of The Royal Society Interface · doi:10.1098/rsif.2013.1035 · Cited by 13
“A strategy for increasing drug potency while decreasing drug concentration is the use of multidrug cocktails [21].”
BackgroundBuelvas, N., Ugarte-Vio, I., Ascencio-Leal, L., Muñoz-Uribe, M., Martin-Martín, A., Rojas‐Fernández, A., Jara, J. A., Tapia, J. C., Arias, M. E., & López‐Muñoz, R. (2023) · Biomolecules · doi:10.3390/biom13091383 · Cited by 10
Sun, X., Zheng, X., Zhang, J., Zhou, T., Yan, G., & Zhu, W. (2015) · FEBS Letters · doi:10.1016/j.febslet.2015.07.014 · Cited by 10
“To examine whether the combination of the cyclin D1-inhibtor and STAT3-inhibitor had a synergistic effect, we adopted the Bliss combination index [18,19] as follows:”
MethodIn vitro approach to predict post-translational phosphorylation response to mixtures
Boyd, J. W., Vrana, J. A., & Currie, H. N. (2012) · Toxicology · doi:10.1016/j.tox.2012.10.010 · Cited by 10
Assessing Combinational Drug Efficacy in Cancer Cells by Using Image-based Dynamic Response Analysis
Sima, C., Hua, J., Cypert, M., Miller, T. M., Wilson-Robles, H. M., Trent, J. M., Dougherty, E. R., & Bittner, M. L. (2015) · Cancer Informatics · doi:10.4137/cin.s30799 · Cited by 11
“To detect such synergistic effects, researchers often assume one of the two widely used models 11 : if the component drugs in the combination are assumed to exert their inhibition through independent mechanisms, one would use the Bliss independence model 12 and expect synergism, if the percentage…”
BackgroundMethodProbing the chemical–biological relationship space with the Drug Target Explorer
Allaway, R. J., Rosa, S. L., Guinney, J., & Gosline, S. J. C. (2018) · Journal of Cheminformatics · doi:10.1186/s13321-018-0297-4 · Cited by 10
Maqbool, T., Hadi, F., Razzaq, S., Naz, S., Aftab, S., Khurshid, S., Awan, S. J., Nawaz, A., Abid, F., & Malik, A. (2021) · Asian Pacific Journal of Cancer Prevention · doi:10.31557/apjcp.2021.22.3.843 · Cited by 10
“Many people have envisioned drug combinations as promising methods of treating complex diseases such as inflammation, cancer and type 2 diabetes (Feala et al., 2010; Fitzgerald et al., 2006; Keith et al., 2005).”
BackgroundSchüttler, A., Jakobs, G., Fix, J. M., Krauss, M. K. V., Krüger, J., Leuthold, D., Altenburger, R., & Busch, W. (2021) · Environmental Health Perspectives · doi:10.1289/ehp7773 · Cited by 10
“With the help of kinetic modeling, Fitzgerald et al. (2006) showed that such more-than-additive or, if one likes, synergistic, e ff ects may occur due to the topology of the a ff ected pathway.”
Abdel‐Halim, H., Hajar, M., Hasouneh, L., & Abdelmalek, S. M. A. (2022) · Drug Design Development and Therapy · doi:10.2147/dddt.s366423 · Cited by 11
“Once established, synergistic combinations achieve more potent therapeutic effects, decreasing the dose used and thus a reducing observed side effects.(32,33) Synergistic drug combination is particularly useful in drug repurposing as many of the identified active compounds show weak activities and do not give the requ…”
BackgroundWorkman, P., & Collins, I. (2014) · Elsevier eBooks · doi:10.1016/b978-0-12-396521-9.00001-2 · Cited by 10
p70S6 kinase is a critical node that integrates HER-family and PI3 kinase signaling networks
Axelrod, M. J., Gordon, V. L., Mendez, R. E., Leimgruber, S., Conaway, M. R., Sharlow, E. R., Jameson, M. J., Gioeli, D. G., & Weber, M. J. (2014) · Cellular Signalling · doi:10.1016/j.cellsig.2014.03.013 · Cited by 11
“Synergy was assessed by comparing observed values and values that would be predicted by Bliss-independence [23,24] and by testing for interactions terms in the two-way ANOVA.”
Sumi, H., Inazuka, M., Morimoto, M., Hibino, R., Hashimoto, K., Ishikawa, T., Kuida, K., Smith, P. G., Yoshida, S., & Yabuki, M. (2016) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2016.10.058 · Cited by 11
A re-engineered immunotoxin shows promising preclinical activity in ovarian cancer
Kollmorgen, G., Palme, K., Seidl, A., Scheiblich, S., Birzele, F., Wilson, S., Clemens, C., Voß, E., Kaufmann, M., Hirzel, K., et al. (2017) · Scientific Reports · doi:10.1038/s41598-017-17329-7 · Cited by 10
Rivera-Robles, M. J., Medina‐Velázquez, J., Asencio-Torres, G. M., González‐Crespo, S., Rymond, B. C., Rodríguez-Medina, J. R., & Dharmawardhane, S. (2018) · Small GTPases · doi:10.1080/21541248.2018.1495008 · Cited by 10
“This suggests that the interaction observed between Cdc42 knockdown and MBQ-167 treatment are probably due to both modes targeting the same protein, and can be interpreted as a possible competitive interaction between the treatments [40,42,48].”
BackgroundDemirsoy, Ş., Tran, H., Liu, J. N., Li, Y., Yang, S., Aregawi, D. G., Glantz, M. J., Jacob, N. K., Walter, V., Schell, T. D., et al. (2024) · Cancers · doi:10.3390/cancers16122253 · Cited by 9
“The Bliss difference was calculated as described previously [47].”
MethodLuo, F., Ling, F., Geng, T., Liu, G., Jiang, C., & Wang, G. (2016) · Aquaculture · doi:10.1016/j.aquaculture.2016.03.045 · Cited by 9
Shen, J., Li, L., Howlett, N. G., Cohen, P. S., & Sun, G. (2020) · Cancers · doi:10.3390/cancers12051087 · Cited by 10
“The development of a systematic and mechanism-based mathematical model for formulating drug combinations would greatly enhance the development of combination therapy for multi-driver cancers [53].”
BackgroundCai, C., & Yu, X. H. (2020) · Journal of Cellular and Molecular Medicine · doi:10.1111/jcmm.15768 · Cited by 9
Pargi, M., Raviraj, S. K. J., Narayanappa, P., Urumarudappa, S. K. J., Malleshappa, P., & Malleshappa, K. H. (2022) · Anti-Cancer Agents in Medicinal Chemistry · doi:10.2174/1871520622666220201103431 · Cited by 9
Dong, X., Katzbaer, R. R., Chitara, B., Han, L., Yang, L., Schaak, R. E., & Yan, F. (2022) · Environmental Science Nano · doi:10.1039/d2en00361a · Cited by 9
“51 To achieve a maximal synergistic effect, the determinations of the reagent type, combination ratio, reaction conditions, and screening methods are essential.”
Screening of Anti-Infectives against Leishmania donovani
Nettey, H., Allotey-Babington, G. L., N’guessan, B. B., Afrane, B. A., Tagoe, M., Ababio, A., Botchway, P., Darko, Y., Sasu, C., & Nyarko, A. K. (2016) · Advances in Microbiology · doi:10.4236/aim.2016.61002 · Cited by 9
“Drug synergy, the combined boost of drug efficacy, is a highly pursued goal of combinational drug development [13].”
BackgroundExperimental Design for Multi-drug Combination Studies Using Signaling Networks
Huang, H., Fang, H., & Tan, M. T. (2017) · Biometrics · doi:10.1111/biom.12777 · Cited by 9
“These advances have also made available large number of potential agents and call for new quantitative approaches for combination therapy (Fitzgerald et al., 2006; Hopkins, 2008; Xavier and Sander, 2010).”
BackgroundComputational modelling of LY303511 and TRAIL-induced apoptosis suggests dynamic regulation of cFLIP
Shi, Y., Mellier, G., Huang, S., White, J., Pervaiz, S., & Tucker‐Kellogg, L. (2012) · Bioinformatics · doi:10.1093/bioinformatics/bts702 · Cited by 9
“For treating cancers, some of the current standards of care are combination therapies, but the development of synergistic combinations has been an expensive and laborious process of empirical testing (Fitzgerald et al., 2006).”
Combination therapy synergism prediction for virus treatment using machine learning models
Majidifar, S., Zabihian, A., & Hooshmand, M. (2024) · PLoS ONE · doi:10.1371/journal.pone.0309733 · Cited by 8
Martín, F., Alcon, C., Marín, E., Morales-Sánchez, P., Manzano-Muñoz, A., Díaz, S., García, M. L. P., Samitier, J., Lu, A., Villanueva, A., et al. (2025) · Cell Death and Disease · doi:10.1038/s41419-025-07513-3 · Cited by 10
Balabanov, S., Wilhelm, T., Venz, S., Keller, G., Scharf, C., Pospisil, H., Braig, M., Barett, C., Bokemeyer, C., Walther, R., et al. (2013) · PLoS ONE · doi:10.1371/journal.pone.0053668 · Cited by 8
“Experimentally derived doseresponse surfaces from combinatorial drug experiments can be used to identify simplified or detailed models for the respective MoA’s and their interactions from analysis of the combinatorial drug response surfaces [18,19,20].”
BackgroundCancer classification: Mutual information, target network and strategies of therapy
Hsu, W.-C., Liu, C.-C., Chang, F., & Chen, S. (2012) · Journal of Clinical Bioinformatics · doi:10.1186/2043-9113-2-16 · Cited by 10
“In [17], mathematical models are used to measure the effect generated by the multiple components.”
MethodYin, A., Yamada, A., Stam, W. B., van Hasselt, J. G. C., & van der Graaf, P. H. (2018) · British Journal of Pharmacology · doi:10.1111/bph.14385 · Cited by 8
“The increasing availability of targeted therapeutic agents has raised interest in rationally developing combination therapies associated with improved efficacy profiles or reduction of side effects (Fitzgerald et al., 2006; Al-Lazikani et al., 2012).”
BackgroundPrediction of drug synergy score using ensemble based differential evolution
Singh, H., Rana, P. S., & Singh, U. (2019) · IET Systems Biology · doi:10.1049/iet-syb.2018.5023 · Cited by 8
Kim, M. S., & Yoon, B.-J. (2012) · BMC Genomics · doi:10.1186/1471-2164-13-s6-s12 · Cited by 8
“In fact, multi-target therapeutics based on combinatory drugs are known to be much more effective, and they are commonly used these days for treating various diseases [1-6].”
BackgroundSystems biology–the transformative approach to integrate sciences across disciplines
Madhavan, M., & Mustafa, S. M. (2022) · Physical Sciences Reviews · doi:10.1515/psr-2021-0102 · Cited by 17
Kaushik, A. C., Mehmood, A., Wei, D., Nawab, S., Sahi, S., & Kumar, A. (2023) · Royal Society of Chemistry eBooks · doi:10.1039/9781839166037 · Cited by 8
Polypharmacological strategies for infectious bacteria
Leitão, M. M., Gonçalves, A. S. C., Borges, F., Simões, M. V., & Borges, A. D. S. (2025) · Pharmacological Reviews · doi:10.1016/j.pharmr.2025.100038 · Cited by 9
Li, X., Zhang, Y., Shen, P.-J., Xu, Y., Gao, Q., Cheng, H., Wang, W., Gu, Z., & Chen, X. (2021) · Journal of the World Aquaculture Society · doi:10.1111/jwas.12806 · Cited by 7
Model‐based prediction of progression‐free survival for combination therapies in oncology
Baaz, M., Cardilin, T., & Jirstrand, M. (2023) · CPT Pharmacometrics & Systems Pharmacology · doi:10.1002/psp4.13003 · Cited by 7
Convergent Evolution of Medicines
De, K., Li, X., & Zhang, H. (2008) · ChemMedChem · doi:10.1002/cmdc.200800093 · Cited by 7
Multifunctional Nanoscale Platforms for Targeting of the Cancer Cell Immortality Spectrum
Soundararajan, V., Warnock, K., & Sasisekharan, R. (2010) · Macromolecular Rapid Communications · doi:10.1002/marc.200900596 · Cited by 7
Mu, D., Qin, H., Jiao, M., Hua, S., & Sun, T. (2021) · Journal of Zhejiang University SCIENCE B · doi:10.1631/jzus.b2000540 · Cited by 7
Detection of Synergistic Combinatorial Perturbations by a Bifurcation-Based Approach
Luo, M., Huang, D., Jiao, J., & Wang, R. (2021) · International Journal of Bifurcation and Chaos · doi:10.1142/s0218127421501753 · Cited by 8
Synergistic Activities of Amoxicillin and Erythromycin Against Bacteria of Medical Importance
Olajuyigbe, O. O., & Animashaun, T. (2012) · Pharmacologia · doi:10.5567/pharmacologia.2012.450.455 · Cited by 7
Kim, E.-J., Wright, G. A., Zoh, R. S., Patil, B. S., Jayaprakasha, G. K., Callaway, E. S., Ivanov, I. V., Turner, N. D., & Chapkin, R. S. (2018) · European Journal of Cancer Prevention · doi:10.1097/cej.0000000000000465 · Cited by 7
“There is an increasing awareness that the use of synergistic drug and/or dietary bioactive combinations can lower the dose of each constituent and consequently minimize potential adverse effects [1, 2].”
Lindhagen, E., Norberg, M., Kanduri, M., Tobin, G., Säisänen, L., Åberg, M., Gustafsson, M. G., Sundström, C., Rosenquist, R., & Åleskog, A. (2009) · European Journal Of Haematology · doi:10.1111/j.1600-0609.2009.01248.x · Cited by 6
Chu, T. L., Guan, Q., Nguan, C. Y. C., & Du, C. (2015) · PLoS ONE · doi:10.1371/journal.pone.0144735 · Cited by 6
“The three types of interaction index are antagonism (negative interaction), additive (no interaction) and synergy (positive interaction) [20, 22].”
BackgroundMethodRecent Progress in Synthesis and Applications of Zinc Phosphate Nanoparticles: A Review
Shathi, T. S., Rahman, M. A., Ahmad, H., & Karim, M. R. (2022) · Journal of nano research · doi:10.4028/p-32n2t8 · Cited by 7
Selecting Genes for Cancer Classification Using SVM: An Adaptive Multiple Features Scheme
Hsu, W.-C., Liu, C.-C., Chang, F., & Chen, S. (2013) · International Journal of Intelligent Systems · doi:10.1002/int.21625 · Cited by 6
Metadata
- Authors
- Fitzgerald, J. B., Schoeberl, B., Nielsen, U. B., & Sorger, P. K.
- Affiliations
- Merrimack Pharmaceuticals (United States) (US)
- Harvard University (US)
- Corresponding author
- Sorger, Peter K
- Venue
- Nature Chemical Biology
- Published
- 2006-08-18
- Volume
- 2
- Issue
- 9
- Pages
- 458-466
- ISSN
- 1552-4450 (ISSN-L)
- 1552-4469
- OpenAlex
- W1994663540
- Cited by
- 570
- References
- 68
- Citations by year
- 2026: 14 · 2025: 15 · 2024: 23 · 2023: 28 · 2022: 30 · 2021: 23 · 2020: 32 · 2019: 36 · 2018: 39 · 2017: 40 · 2016: 45 · 2015: 41 · 2014: 45 · 2013: 34 · 2012: 36
- FWCI
- 12.93
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Nature Chemical Biology (publishedVersion)
- PubMed (publishedVersion)
- Funders
- National Institutes of Health (5p50gm068762-10)
- National Institute of General Medical Sciences (GM 68762)
- Topics
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Drug Discovery › Computational Drug Discovery Methods
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Gene Regulatory Network Analysis
- Physical Sciences › Mathematics › Modeling and Simulation › Mathematical Biology Tumor Growth
- Keywords
- combination therapy, systems biology, targeted therapy, therapeutic index, personalized medicine, cytotoxic chemotherapy
- MeSH terms
- Drug Therapy, Combination, Models, Biological, Feedback, Physiological, Systems Biology
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.